A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness

Trial Profile

A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs ARGX 113 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Proof of concept
  • Sponsors argenx
  • Most Recent Events

    • 04 May 2017 According to an argenx media release, the company has recruited 50% of the myasthenia gravis (MG) patients in this trial. Top-line data from the study are expected in first quarter of 2018.
    • 15 Mar 2017 Accordnig to an argenx media release, the first patient has been dosed in this trial.
    • 09 Jan 2017 According to an arGEN-X media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top